Prescription ·Strong evidence ·Reviewed May 2026
Rivastigmine is a cholinesterase inhibitor used for dementia due to Alzheimer disease and Parkinson disease. It is available as oral capsules/solution and as a transdermal patch, with the patch often improving gastrointestinal tolerability. Key safety concerns include nausea, vomiting, weight loss, bradycardia, syncope, falls, and application-site allergic contact dermatitis.
The bottom line
Evidence rating strong. Most-documented uses: symptomatic treatment of mild to moderate alzheimer disease dementia, symptomatic treatment of dementia associated with parkinson disease, severe alzheimer disease treatment with higher-dose patch in labeled use. 3 sources indexed (2004–2026), with 4 interaction records on file.
Core mechanism
Rivastigmine inhibits acetylcholinesterase and butyrylcholinesterase, increasing acetylcholine availability in cortical and subcortical cholinergic pathways affected by neurodegenerative disease. Enhanced cholinergic signaling may modestly improve or stabilize cognition and function in some patients. Peripheral cholinergic effects explain gastrointestinal adverse effects, bradycardia, syncope, bronchospasm risk, urinary effects, and possible seizure-threshold concerns.2,3
Oral rivastigmine should be taken with meals. The patch is applied once daily to clean, dry, hairless skin and rotated to reduce skin reactions.
Ginkgo is often used for cognition but may increase bleeding risk and has seizure case reports. Rivastigmine can cause syncope and may be used in frail patients where adverse events have high consequences.
Recommendation: Avoid unsupervised combination; review bleeding risk, falls, and seizure history with the clinician.
Magnesium can loosen stools, while rivastigmine commonly causes nausea, vomiting, and diarrhea.
Recommendation: Use cautiously if diarrhea, poor intake, dehydration, or weight loss occurs.
Melatonin can add sleepiness or dizziness to rivastigmine-related syncope or fall risk.
Recommendation: Use cautiously and monitor nighttime confusion, falls, and morning sedation.
Ashwagandha may cause sedation or dizziness and can complicate assessment of rivastigmine tolerability.
Recommendation: Avoid during rivastigmine titration; use cautiously if stable and monitor falls or confusion.
Numbered references. Citations throughout the page link here.
Systematic review found symptomatic cognitive and functional benefits with common gastrointestinal adverse effects.
Trial supported rivastigmine benefit in Parkinson disease dementia, with cholinergic adverse effects.
Labeling describes patch dosing, contraindication after allergic contact dermatitis, GI adverse effects, weight loss, and bradycardia cautions.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
